A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma

NCT00516191 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped low accrual

Conditions

Multiple Myeloma

Interventions

DRUG: Liposomal Doxorubicin/Melphalan/Bortezomib

Sponsor

University of California, San Francisco